ESR1 and breast cancer: Thus, CRISPR-Cas9-mediated introduction of mutations in the genomically encoded ESR1 gene would facilitate direct comparison of isogenic wild-type and mutant breast cancer cells towards developing a better understanding of the consequences of these mutations on response to endocrine therapies, and importantly, would enable evaluation of therapeutic approaches to target breast cancers featuring ESR1 mutations.